. 2022 Jun 15;11(3):1235–1252. doi: 10.1007/s40120-022-00370-8

Table 4.

Adverse events for atogepant versus placebo

Outcome or subgroup	Number of studies [References]	Number of pooled events/participants		I²	Risk ratio (95% CI)	p value
Outcome or subgroup	Number of studies [References]	Atogepant	Placebo	I²	Risk ratio (95% CI)	p value
Atogepant 10 mg
Any AE	2 [23, 24]	178/314	218/408	85.1%	1.11 (0.78–1.56)^a	0.566
Any SAE		3/314	4/408	0.0%	1.00 (0.22–4.54)	0.997
Discontinuation due to AEs		13/314	11/408	0.0%	1.54 (0.69–3.42)	0.289
Constipation		19/314	5/408	80.5%	3.93 (0.20–76.09)^a	0.365
Nasopharyngitis		7/314	12/408	22.2%	0.75 (0.31–1.84)	0.532
Nausea		16/314	13/408	24.9%	1.77 (0.83–3.78)	0.139
Upper respiratory tract infection		15/314	25/408	0.0%	0.85 (0.45–1.61)	0.620
Urinary tract infection		5/314	12/408	0.0%	0.53 (0.19–1.46)	0.221
Atogepant 30 mg
Any AE	2 [23, 24]	234/411	218/408	84.5%	1.08 (0.79–1.48)^a	0.639
Any SAE		2/411	4/408	0.0%	0.56 (0.12–2.58)	0.453
Discontinuation due to AEs		15/411	11/408	55.0%	1.36 (0.63–2.92)	0.428
Constipation		26/411	5/408	62.3%	5.19 (2.00–13.46)	0.001
Nasopharyngitis		19/411	12/408	48.9%	1.57 (0.77–3.19)	0.211
Nausea		23/411	13/408	0.0%	1.77 (0.91–3.44)	0.093
Upper respiratory tract infection		27/411	25/408	0.0%	1.08 (0.64–1.82)	0.782
Urinary tract infection		20/411	12/408	36.8%	1.65 (0.82–3.34)	0.160
Atogepant 60 mg
Any AE	2 [23, 24]	231/417	218/408	61.1%	1.04 (0.91–1.17)	0.575
Any SAE		2/417	4/408	0.0%	0.55 (0.12–2.54)	0.441
Discontinuation due to AEs		12/417	11/408	0.0%	1.07 (0.48–2.39)	0.872
Constipation		25/417	5/408	66.4%	4.92 (1.89–12.79)	0.001
Nasopharyngitis		22/417	12/408	67.3%	1.80 (0.90–3.58)	0.096
Nausea		36/417	13/408	0.0%	2.73 (1.47–5.06)	0.001
Upper respiratory tract infection		19/417	25/408	0.0%	0.75 (0.42–1.33)	0.324
Urinary tract infection		14/417	12/408	0.0%	1.14 (0.53–2.43)	0.740

AE adverse event, CI confidence interval, SAE serious adverse event

^aRisk ratio from random-effect model.